期刊文献+

Genistein对体外培养的大鼠多巴胺能神经元的保护作用

The neuroprotective effects of genistein on dopaminergic neurons of rats in vitro
下载PDF
导出
摘要 为了探讨genistein(GST)对离体培养的Parkinson模型多巴胺能神经元的保护作用,本实验取孕14~16 d的SD大鼠胚胎中脑腹侧,常规体外培养。将培养细胞分为四组:正常对照组、E2+MPP+组、GST+MPP+组、MPP+组。用免疫细胞化学染色法观察培养物中TH阳性神经元的生长状况、观察神经元中微管相关蛋白-2(MAP-2)的染色情况。通过突触素(SYN)免疫荧光染色,观察各实验组突触数量的变化。结果显示:与正常对照组、E2+MPP+组以及GST+MPP+组相比,MPP+组TH阳性神经元数量少,SYN免疫阳性产物表达亦减少(P<0.05);MAP-2阳性染色的平均灰度减少约40%左右。而E2+MPP+组、GST+MPP+组中上述指标与正常对照组相比,差异无统计学意义(P>0.05)。本研究结果表明genistein对体外培养的多巴胺能神经元具有类似雌激素样的神经保护作用。 To explore the neuroprotective effects of genistein on dopaminergic neurons injured by 1 -methyl-4-phenylpyridium ion ( MPP ^+ ) in culture in vitro, the neurons from ventral mesencephalon of E14-16 SD rat were cultured and divided into four groups with different mediums : the control group, E2 + MPP ^+ group, GST + MPP ^+ group and MPP + group. Using tyrosine hydroxylase (TH) immunocytochemical staining method to observe morphology and development of dopaminergic neurons, microtubule-associated protein-2 ( MAP-2 ) immunocytochemistry to show the dyeing status of neurons. The cultured neurons were stained with immunoflorescence by using antibody for synaptophysin (SYN) to observe the number change of synapses. The results showed that the number of the TH positive neurons and the SYN immunoreactive products in MPP ^+ group were low in comparison with those in control, E2 + MPP ^+ or GST + MPP ^+ groups (P 〈 0.05). Meanwhile, the average gray scale of MAP-2 positive staining in MPP ^+ group reduced about 40%. However, no significant difference between control group, E2 + MPP + group and GST + MPP ^+ group were observed ( P 〉 0.05 ). The present results suggest that genistein has neuroprotective effects similar to estrogen on dopaminergic neurons in vitro.
出处 《神经解剖学杂志》 CAS CSCD 北大核心 2008年第6期631-635,共5页 Chinese Journal of Neuroanatomy
关键词 GENISTEIN 多巴胺能神经元 突触素 大鼠 genistein, dopaminergic neurons, synaptophysin, rat
  • 相关文献

参考文献15

  • 1Wu RM, Chen RC, Chiueh CC. Effect of MAO-B inhibitors on MPP^+ toxicity in vivo. Ann N Y Acad Sci, 2000;899:255 -261
  • 2Dauer W, Przedborski S. Parkinson's disease: Mechanisms and models. Neuron, 2003 ;39:889 -909
  • 3Bauer RB, Stevens C, Reveno WS et al. L-dopa treatment of Parkinson's disease: a ten-year follow up study. J Am Geriatr Soc, 1982 ;30:322 - 325
  • 4Li SC, Schoenberg BS, Wang CC et al. A prevalence survey of Parkinson's disease and other movement disorders in the People's Republic of China. Arch Neurol, 1985 ;42:655 - 657
  • 5Sandyk R. Estrogens and the pathophysiology of Parkinson's disease. Int J Neurosci, 1989 ;45 : 119 - 122
  • 6Leranth C, Roth RH, Elsworth JD et al. Estrogen is essential for maintaining nigrostriatal dopamine neurons in primates: implications for Parkinson's disease and memory. Neuroscience, 2000; 20:8604 - 8609
  • 7Liu LX, Chen WF, Xie JX et al. Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease. Neurosci Res, 2008 ;60 : 156 - 161
  • 8孟庆书,何平,朱晓燕,倪鑫.植物雌激素的作用机制[J].生命的化学,2007,27(2):141-143. 被引量:22
  • 9Zava DT, Duwe G. Estrogenic and antiproliferative properties of genistein and other flavonoids in human breast cancer cells in vitro. Nutr Cancer, 1997 ;27:31 -40
  • 10Shughrue PJ, Lane MV, Merchenthaler I. Comparative distribution of estrogen receptor-α and receptor-β mRNA in the rat central nervous system. J Comp Neurol, 1997 ;388:507 -525

二级参考文献27

  • 1Fukuda M, Edwards C, Eidelberg D. Functional brain networks in Parkinsou' s disease [ J ]. Parkinsonism Related Disord, 2001, 8 (2):91-94.
  • 2Hu MT, Taylor-Robinson SD, Chaudhuri KR, et al. Cortical d ysfunction in non-demented Parkinson' s disease patients: a combined31P-MRS and 18FDG-PET study[J]. Brain, 2000, 123(2): 340-352.
  • 3Kikuchi A, Takeda A, Kimpara T, et al. Hypoperfusion in the supplementary motor area, dorsolateral prefrontal cortex and insular cortex in Parkinson's disease[J]. Neurol Sci, 2001, 193(1):29-36.
  • 4Sabatini U, Boulanouar K, Fabre N, et al. Cortical motor reorganization in akinetic patients with Parkinson's disease: a functional MRI study[J]. Brain, 2000, 123(2): 394-403.
  • 5Glantz LA, Lewis DA. Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia: regional and diagnositic specificity [ J ]. Archives of General Psychiatry, 1997, 54(7): 660-669.
  • 6Masliah E. Deficient glutamate transport is associated with neurodegeneration in Alzheimer' s diease [ J ]. Annal Neurol, 1996, 40(5): 759-766.
  • 7AI-Chalabi A, Miller CC. Neurofilaments and neurological disease[J].Bioessays, 2003, 25(4): 346-355.
  • 8Jellinger KA. Recent developments in the pathology of Parkinson' s disease[J]. Neural Transm Suppl, 2002, 62 (3): 347-376.
  • 9Nakao N, Ogura M, Nakai K. Intrastriatal mesencephalic grafts affect neuronal activity in basal ganglia nuclei and their target structures in rat model of Parkinson's disease[J]. Neurosc, 1998, 18(5): 1806-1817.
  • 10Saito S, Kobayashi S, Ohashi Y, et al. Decreased synaptic density in aged brain and its prevention by rearing under enriched environmentas revealed by synaptophysin contents [ J]. Neurosci Res, 1994, 39 ( 1 ):57-62.

共引文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部